The effectiveness of pharmacological agents for the treatment of uveitic macular oedema UMO: a systematic review protocolReportar como inadecuado




The effectiveness of pharmacological agents for the treatment of uveitic macular oedema UMO: a systematic review protocol - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Systematic Reviews

, 5:29

First Online: 13 February 2016Received: 13 November 2015Accepted: 02 February 2016DOI: 10.1186-s13643-016-0203-y

Cite this article as: Tallouzi, M.O., Moore, D.J., Calvert, M. et al. Syst Rev 2016 5: 29. doi:10.1186-s13643-016-0203-y

Abstract

BackgroundMacular oedema MO describes the accumulation of fluid in the central part of the retina, known as the ‘macula’ which provides central vision. MO is the leading cause of sight loss in patients with intraocular inflammation uveitis. There is a lack of consensus over the treatment of uveitic macular oedema UMO. The proposed systematic review will evaluate the evidence on the effectiveness of pharmacological agents used to treat UMO. All systemic, local, or topical pharmacological agents will be included.

Method-designStandard systematic review methodology will be employed to identify, select and extract data from comparative studies randomised-non-randomised trials and observational studies of the pharmacological interventions in patients with UMO. Searches will be conducted through bibliographic databases Cochrane Library, MEDLINE, EMBASE and CINAHL and clinical trials registers. No restriction will be placed on either language or year of publication. Translation of non-English language articles will be undertaken to minimise selection bias. The primary outcome of interest will be best corrected visual acuity and secondary outcomes will be adverse events, health-related quality of life, assessment of UMO using central macular thickness e.g. by optical coherence topography OCT, clinical and angiographic assessment of UMO, clinical estimation of vitreous haze. Risk of bias assessment appropriate to each study design will be undertaken. Data will be grouped by comparison, tabulated and narratively synthesised. Meta-analysis will be undertaken where clinical and methodological homogeneity exists. Subgroup and sensitivity analyses, also network analyses and intra-inter-pharmacological class analyses will be undertaken where deemed appropriate.

DiscussionA number of published studies have investigated the effectiveness of the pharmacological agents used to treat UMO. However, there is no recent systematic review that synthesises this evidence. This systematic review will analyse the effectiveness of systemic, local and topical therapies to treat UMO. The findings will provide important evidence to inform clinical and health policy decision-making for the treatment of UMO.

Systematic review registrationProspero CRD42015019170

KeywordsSystematic review Macular oedema Macular edema Uveitis Management Pharmacological agents Meta-analysis AbbreviationsAnti-VEGFanti-vascular endothelia growth factor

BCVAbest corrected visual acuity

CENTRALCochrane Central Register of Controlled Trials

CINAHLCumulative Index to Nursing and Allied Health Literature

ETDRSEarly Treatment Diabetic Retinopathy Study

MEDLINEMedical Literature Analysis and Retrieval System Online

NICENational Institute for Health and Care Excellence

OCToptical coherence topography

PRISMAPreferred Reporting Items for Systematic Reviews and Meta-analyses

TNFtumour necrosis factor

UMOuveitic macular oedema

Electronic supplementary materialThe online version of this article doi:10.1186-s13643-016-0203-y contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Mohammad O. Tallouzi - David J. Moore - Melanie Calvert - Philip I. Murray - Nicholas Bucknall - Alastair K. Denniston

Fuente: https://link.springer.com/







Documentos relacionados